Literature DB >> 31501860

Facilitating access to new therapeutic options through clinical trials: the vision of a regulator to reconcile innovation and safety.

S Vignot1, M Martin2, N Albin2, C Schurtz2, E Chapel2.   

Abstract

Mesh：

Year:  2019        PMID： 31501860     DOI： 10.1093/annonc/mdz389

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  3 in total

1.  Recommendations from national regulatory agencies for ongoing cancer trials during the COVID-19 pandemic.

Authors:  Bruno H R de Paula; Indiara Araújo; Lívia Bandeira; Nathália M P B Barreto; Gary J Doherty
Journal:  Lancet Oncol       Date:  2020-04-08       Impact factor: 41.316

2.  Impact of the COVID-19 Pandemic on Oncology Clinical Research in Latin America (LACOG 0420).

Authors:  Aline B Lara Gongora; Gustavo Werutsky; Denis L Jardim; Angelica Nogueira-Rodrigues; Carlos H Barrios; Clarissa Mathias; Fernando Maluf; Rachel Riechelmann; Maurício Fraga; Henry Gomes; William N William; Camilla A F Yamada; Gilberto de Castro; Daniela D Rosa; Andreia C de Melo; Raul Sala; Eva Bustamante; Denisse Bretel; Oscar Arrieta; Andrés F Cardona; Diogo A Bastos
Journal:  JCO Glob Oncol       Date:  2021-04

3.  Impact of the COVID-19 Pandemic on Non-COVID-19 Clinical Trials.

Authors:  Katia Audisio; Hillary Lia; Newell Bryce Robinson; Mohamed Rahouma; Giovanni Soletti; Gianmarco Cancelli; Roberto Perezgrovas Olaria; David Chadow; Derrick Y Tam; Dominique Vervoort; Michael E Farkouh; Deepak L Bhatt; Stephen E Fremes; Mario Gaudino
Journal:  J Cardiovasc Dev Dis       Date:  2022-01-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.